Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis[S]

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis[S]

Fibroblast growth factor (FGF)19, an endocrine hormone produced in the gut, acts in the liver to control bile acid synthesis. NGM282, an engineered FGF19 analog, is currently in clinical development for treating nonalcoholic steatohepatitis. However, the molecular mechanisms that integrate FGF19 wit...

Full description

Bibliographic Details
Main Authors: Mei Zhou, R. Marc Learned, Stephen J. Rossi, Hui Tian, Alex M. DePaoli, Lei Ling
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Journal of Lipid Research
Subjects:
adenosine 5′-triphosphate-binding cassette transporter A1
bile acid metabolism
cholesterol 7-alpha hydroxylase
clinical studies
liver
nuclear receptor liver X receptor
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520326183

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520326183

Similar Items